These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 30256723)

  • 1. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 3. Sodium-glucose Cotransporter 2 Inhibitors: Impact on Body Weight and Blood Pressure Compared with other Antidiabetic Drugs.
    Imprialos KP; Stavropoulos K; Stavropoulos N; Patoulias D; Petidis K; Grassos C; Dimitriadis K; Tsioufis C
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):104-113. PubMed ID: 29412121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT-2 Inhibitors: Fighting Cardiovascular Disease Mortality in Diabetes.
    Ghaffar ZA; Anwar S; Rizvi SW
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):195. PubMed ID: 30700368
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT-2 inhibitors and GLP-1 receptor agonists.
    Bonaventura A; Carbone S; Dixon DL; Abbate A; Montecucco F
    J Intern Med; 2019 Jul; 286(1):16-31. PubMed ID: 30888088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?
    Santos-Ferreira D; Gonçalves-Teixeira P; Fontes-Carvalho R
    Cardiology; 2020; 145(5):311-320. PubMed ID: 31865310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
    Weir MR
    Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Outcome studies on SGLT-2 inhibitors].
    Seufert J; Laubner K
    Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors.
    Reid T
    J Fam Pract; 2021 Jul; 70(6S):S1-S6. PubMed ID: 34432617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
    Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
    Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose Cotransporter 2 Inhibitors: Potential Cardiovascular and Mortality Benefits.
    Lovic D; Pittaras A; Kallistratos M; Tsioufis C; Grassos C; Djordjevic D; Tasic I; Manolis A
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):114-119. PubMed ID: 29485012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.
    Lu J; Tang L; Meng H; Zhao J; Liang Y
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3169. PubMed ID: 30974510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
    Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
    Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.
    Giugliano D; Longo M; Scappaticcio L; Caruso P; Esposito K
    Cardiovasc Diabetol; 2021 Jan; 20(1):17. PubMed ID: 33430860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.
    Ahmed HM; Khraishah H; Cho L
    Eur Heart J; 2018 Jul; 39(25):2368-2375. PubMed ID: 29236983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors.
    Lahnwong C; Chattipakorn SC; Chattipakorn N
    Cardiovasc Diabetol; 2018 Jul; 17(1):101. PubMed ID: 29991346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms.
    Lee PC; Ganguly S; Goh SY
    Obes Rev; 2018 Dec; 19(12):1630-1641. PubMed ID: 30253050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
    Flores E; Santos-Gallego CG; Diaz-Mejía N; Badimon JJ
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):213-222. PubMed ID: 29679303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.